top of page
it's where dermatology lives


press to zoom

press to zoom

press to zoom
1/2


mRNA vaccine/pembrolizumab combo reduces post-surgery melanoma recurrence, death risk
In a new study, adding an individualized mRNA-based vaccine to post-surgery pembrolizumab immunotherapy for high-risk melanoma reduced the risk of melanoma recurrence or death by 42% compared with pembrolizumab alone. The findings were announced in a presentation at the ESMO (European Society for Medical Oncology) Congress 2026 in Madrid. According to a press release from the Melanoma Institute Australia, positive results in melanoma suggest this personalized approach may ena
John Evans
Oct 302 min read


ABL1, ABL2 drive MAPK resistance and immune suppression in melanoma
New research shows that melanoma cells not only develop resistance to MAPK (Mitogen-Activated Protein Kinase) inhibitors commonly used to treat it, but also actively suppress the immune cells that would otherwise help eliminate melanoma. The study, published in Nature Communications, identified two cell proteins, ABL1 and ABL2, as key drivers of both processes. These proteins help control cell functions such as growth, survival, and communication with other cells, and when th
John Evans
Oct 232 min read


VIDEO: Children of melanoma survivors have twice the lifetime risk of melanoma
Children of parents who have been diagnosed with melanoma are twice as likely to develop melanoma themselves, due to biological factors, environmental factors, and behaviours.
Jeremy Visser
Oct 201 min read


Early diagnosis and excision of melanoma during pregnancy key to better outcomes
Melanoma should be identified during pregnancy and then excised, since a delay in management may create an opportunity for a melanoma to advance. That’s according to Dr. Jane Margaret Grant-Kels, Professor of Dermatology, Pathology and Pediatrics, University of Connecticut School of Medicine, Farmington, Conn. Speaking at a session on the evaluation and treatment of pregnant patients at the annual meeting of the American Academy of Dermatology (AAD) in Denver, Dr. Grant-Kels
John Evans
Sep 182 min read


VIDEO: Immune cells may predict melanoma treatment outcomes
Changes to white blood cell counts have been linked to different survival outcomes in melanoma patients
Jeremy Visser
Sep 11 min read


Macrophage communication failure key in NMSC
Researchers at The University of Texas MD Anderson Cancer Center have discovered that immunosuppressed patients with non-melanoma skin cancer are not missing the key cancer-fighting macrophages found in immunocompetent patients. Instead, those cells have lost the ability to communicate effectively. The researchers say this new understanding may help researchers develop new treatment approaches for these aggressive skin cancers. The study was published in Cell. Moran Amit, MD,
John Evans
Aug 72 min read


Dissolving microneedles could help PDT reach deeper skin tumours
In photodynamic therapy, a light-sensitive drug accumulates in cancer cells and is then activated by light, producing cell-killing molecules. Microneedles can help deliver the drug and distribute light more effectively within non-melanoma skin cancer. Image by M. Requena et al. A biodegradable microneedle patch designed to deliver treatment through the skin may also guide and scatter light, potentially allowing photodynamic therapy (PDT) to treat nonmelanoma skin cancers more
Allan Ryan
Jul 272 min read


Impact of radiotherapy on CTCL immune environment characterized
Immune trajectory shifts in the pre- to post-radiotherapy (RT) tumour microenvironment in cutaneous T-cell lymphoma. Courtesy of Alan Zhou, MD, ‘21 MSc. Researchers have discovered how radiotherapy alters the immune environment within cutaneous T-cell lymphoma (CTCL) tumours, according to findings published in the Journal of the American Academy of Dermatology. The study reveals how radiotherapy not only eliminates cancer cells but also reprograms the surrounding tumour micro
John Evans
Jul 103 min read
Featured Posts


bottom of page
